ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,423Medicare Part D Prescriptions Filled, Including Refills

Rank: 21 out of 315

$587K Total Retail Price of All Prescriptions

Rank: 49 out of 315

469 Patients Receiving at Least One Drug in Part D
94%Patients 65 Years and Older
27% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Hawaii
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

10% of this provider’s 469 patients filled at least one prescription for a schedule three drug, compared to an average of 6%.

Risky Drugs to Seniors

1% of this provider’s 10,948 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 27%.

Prescription Price

$51 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

24 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Hawaii
SIMVASTATIN 871 819 1 1
AMLODIPINE BESYLATE 471 463 2 2
LISINOPRIL 388 387 3 3
METOPROLOL SUCCINATE 385 371 4 13
ATORVASTATIN CALCIUM 384 363 5 5
GLIPIZIDE 318 309 6 30
LISINOPRIL-HYDROCHLOROTHIAZIDE 306 284 7 50
METFORMIN HCL 282 265 8 7
FUROSEMIDE 279 279 9 15
ATENOLOL 275 272 10 11
PRAVASTATIN SODIUM 268 268 11 10
OMEPRAZOLE 236 224 12 9
LEVOTHYROXINE SODIUM 221 208 13 6
AMLODIPINE BESYLATE-BENAZEPRIL 215 215 14 26
METOPROLOL TARTRATE 209 209 15 18
ALLOPURINOL 202 177 16 14
LOSARTAN-HYDROCHLOROTHIAZIDE 191 191 17 17
HYDROCHLOROTHIAZIDE 190 190 18 16
DIGOXIN 163 150 19 45
TAMSULOSIN HCL 155 155 20 21
FELODIPINE ER 142 141 21 23
CLOPIDOGREL 141 132 22 25
NADOLOL 139 139 23 181
FENOFIBRATE 130 123 24 43
LOSARTAN POTASSIUM 130 130 24 4
WARFARIN SODIUM 119 119 26 20
PANTOPRAZOLE SODIUM 117 91 27 35
ISOSORBIDE MONONITRATE ER 117 105 27 92
CARVEDILOL 114 114 29 22
PLAVIX 107 103 30 40
AZITHROMYCIN 104 95 31 39
HYDROCODONE-ACETAMINOPHEN 102 95 S3 32 19
ONGLYZA 96 92 33 99
DONEPEZIL HCL 83 83 34 28
DOXAZOSIN MESYLATE 81 81 35 110
ADVAIR DISKUS 78 78 36 46
METOLAZONE 76 76 37 284
ZOLPIDEM TARTRATE 75 75 38 29
VERAPAMIL ER 73 59 39 94
SERTRALINE HCL 72 72 40 100
RANITIDINE HCL 72 70 40 42
PROMETHAZINE-CODEINE 69 69 R 42 155
DILTIAZEM 24HR ER 64 64 43 90
POTASSIUM CHLORIDE 63 51 44 36
LOVASTATIN 61 54 45 8
DIOVAN HCT 56 55 46 56
PRADAXA 56 52 46 146
LANTUS SOLOSTAR 52 44 48 69
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 6, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.